Aptose Biosciences (NASDAQ:APTO) Shares Scheduled to Reverse Split on Wednesday, February 26th

Shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) are scheduled to reverse split on the morning of Wednesday, February 26th. The 1-30 reverse split was announced on Tuesday, February 18th. The number of shares owned by shareholders will be adjusted after the market closes on Tuesday, February 25th.

Aptose Biosciences Stock Up 7.6 %

Aptose Biosciences stock traded up $0.01 during trading hours on Tuesday, hitting $0.19. 4,882,723 shares of the company traded hands, compared to its average volume of 5,252,953. The firm has a market cap of $11.65 million, a P/E ratio of -0.07 and a beta of 0.88. The firm’s 50-day simple moving average is $0.21 and its two-hundred day simple moving average is $0.31. Aptose Biosciences has a 1-year low of $0.13 and a 1-year high of $2.01.

Analysts Set New Price Targets

Several equities analysts have commented on APTO shares. HC Wainwright reissued a “buy” rating and set a $2.00 target price on shares of Aptose Biosciences in a research note on Wednesday, February 12th. StockNews.com assumed coverage on shares of Aptose Biosciences in a research note on Monday. They set a “hold” rating on the stock.

Hedge Funds Weigh In On Aptose Biosciences

An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp lifted its holdings in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 401,750 shares of the biotechnology company’s stock after purchasing an additional 167,282 shares during the period. Sigma Planning Corp owned about 2.22% of Aptose Biosciences worth $165,000 at the end of the most recent reporting period. Institutional investors own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.